

# Critical Reading of Clinical Trials

## 1. Introduction

## 2. Internal Validity

- 2.1 Statistical reality of the result
- 2.2 Methodological value of the result
- 2.3 Absence of bias
  - 2.3.1 Confusion bias
  - 2.3.2 Selection bias
  - 2.3.3 Biases linked to the absence or lack of double-blind
  - 2.3.4 Follow-up bias
  - 2.3.5 Evaluation bias
  - 2.3.6 Open trial
  - 2.3.7 Attrition bias
  - 2.3.8 Biases of intention-to-treat analysis
  - 2.3.9 Biases of non-inferiority trials

## 3. External Coherence

- 3.1 Coherence of a positive result
- 3.2 Coherence of a negative result
- 3.3 Explanations for discrepancies

## 4. Clinical Relevance


- 4.1 Objective of the trial
- 4.2 Suitable comparison treatment
- 4.3 Clinical judgment criterion
- 4.4 Concomitant treatments
- 4.5 Treatability of the evaluated treatment
- 4.6 Representativeness of the patients included in the trial
  - 4.6.1 Extrapolation of results
  - 4.6.2 Patients representative of those seen in practice
  - 4.6.3 Determination of the target population
  - 4.6.4 Consequences of grouping too heterogeneous patients
- 4.7 Size and precision of the effect
  - 4.7.1 Confidence interval
  - 4.7.2 Interpretation
- 4.8 Assessment of the benefit-risk balance

- 4.8.1 Side effects more severe than the disease
- 4.8.2 Side effects of the same nature as the disease
- 4.8.3 Summary

## 5. **Special Case of Negative Trials**

- 5.1 Superiority trial
  - 5.1.1 Lack of statistical power
  - 5.1.2 Conservative trial
  - 5.1.3 Real lack of treatment efficacy
- 5.2 Negative non-inferiority trial

## Introduction to critical reading of clinical trials



Clinical trials are pivotal in the realm of medical research. They serve as the cornerstone for **evidence-based practices**, offering insights into the safety, efficacy, and effectiveness of medical interventions, be it drugs, devices, or therapeutic strategies. However, the complexity and diversity of trials necessitate a meticulous approach to reading and interpreting their findings. This is where the art of 'critical reading' comes into play.

Critical reading goes beyond merely understanding the content of a trial; it involves a holistic approach of evaluating the validity, relevance, and applicability of its findings. This process ensures that the conclusions drawn are not only scientifically sound but also clinically relevant. A key aspect of this involves understanding both the **internal and external validity** of a trial.

Internal validity pertains to how well the trial was conducted, free from biases, while external validity concerns the generalizability of the results to broader populations.

Bias, a systemic error that can skew the results of a study, is a significant challenge in clinical trials. **Different types of biases**, from selection bias to attrition bias, can inadvertently introduce errors, thus potentially leading to false conclusions. Recognizing and accounting for these biases is essential for an accurate interpretation of trial outcomes.

Moreover, the **clinical relevance** of a trial's findings is of paramount importance. A treatment might be statistically significant but may not translate to meaningful clinical outcomes. Hence, assessing the real-world applicability and understanding the benefit-risk balance is vital.

Lastly, not all clinical trials yield positive results. Some might show no difference or even negative outcomes. Interpreting such trials requires a different lens, understanding the nuances behind the lack of efficacy or superiority.



## 2. Internal Validity of clinical trials



### 2.1 Statistical Reality of the Result

Statistical reality refers to the genuineness of a trial's results based on its statistical analysis. In clinical trials, it's essential to ensure that observed outcomes aren't just random occurrences but have true scientific merit. For instance, a trial might find that a new drug reduces blood pressure. But is this reduction **statistically significant**, or could it just be due to chance? By applying rigorous statistical methods, researchers aim to ascertain the true effect of an intervention. Proper statistical analysis helps in distinguishing genuine effects from mere random variations.

Example: If a trial finds that a new drug reduces systolic blood pressure by 10 mmHg with a **p-value of 0.01**, it means there's only a 1% probability that this result occurred by chance, indicating a strong statistical reality.

## 2.2 Methodological Value of the Result

The methodological value emphasizes the quality and rigor of the methodologies employed in a trial. A study might have statistically significant results, but if the methods used are flawed, the conclusions might be misleading. Factors like **sample size**, **randomization procedures**, **blinding**, and **control groups** determine the methodological strength of a trial. A well-designed methodology ensures that the results are not only statistically valid but also robust and reproducible in other settings.

Example: A trial with a large sample size, proper randomization, and blinding techniques is more likely to have high methodological value than a trial without these attributes.

## 2.3 Absence of Bias

Bias Type	Definition	Example
<b>Confusion Bias</b>	Error arising from mixing effects of extraneous factors with the intervention's effect	A trial studying the impact of exercise on heart health but doesn't account for participants' diet
<b>Selection Bias</b>	Error due to systematic differences in characteristics between study groups	Excluding elderly patients in a trial meant to study a drug's effect on all age groups
<b>Biases from Lack of Double-Blind</b>	Error because participants or investigators are aware of the treatment allocation	If doctors know who's getting a placebo, they might subconsciously treat those patients differently

<b>Bias Type</b>	<b>Definition</b>	<b>Example</b>
<b>Follow-Up Bias</b>	Error due to differences in follow-up time or frequency between study groups	Participants receiving treatment A are followed up more frequently than those receiving treatment B
<b>Evaluation Bias</b>	Error in the way outcomes are evaluated or measured	Using an inaccurate blood pressure monitor in a trial studying hypertension drugs
<b>Open Trial Bias</b>	Error due to lack of blinding among participants or investigators	Participants know they are receiving a new experimental drug, influencing their reported outcomes
<b>Attrition Bias</b>	Error due to systematic differences in withdrawals or exclusions from a trial	Participants experiencing side effects are more likely to drop out, skewing the trial's safety profile
<b>Intention-to-Treat Analysis Bias</b>	Error due to not analyzing participants based on their original allocated groups	Participants switch from treatment A to B during the trial, but are analyzed under group A
<b>Non-Inferiority Trial Biases</b>	Error in trials meant to prove a new treatment is not worse than an existing one	Setting a too lenient margin of non-inferiority, making it easier for the new treatment to appear as good as old one

### 3. External Validity of clinical trials



#### 3.1 Positive Result's External Coherence

External coherence relates to the extent to which the results of a particular study align with the findings from other studies or established knowledge. When a clinical trial yields a positive result, it's essential to ensure that this outcome isn't an outlier but is **coherent with the broader scientific literature**.



This coherence enhances the confidence in the trial's findings and their applicability in real-world settings.

For example, if a new antihypertensive drug shows a significant reduction in blood pressure in a trial, but numerous other trials on the same drug don't demonstrate this effect, there might be concerns about the external coherence of the positive result. Maybe the population in the successful trial had some unique characteristics, or perhaps the trial had some methodological strengths (or weaknesses) that caused the differential outcome.

Thus, it's crucial not just to celebrate positive results in isolation but to contextualize them within the wider spectrum of scientific evidence. This helps in understanding the nuances and potential limitations, ensuring that the findings can be generalizable and reliable in diverse settings and populations.

### **3.2 Negative Result's External Coherence**

Just as with positive results, negative outcomes in clinical trials also need scrutiny for external coherence. If a trial concludes that a particular intervention doesn't work, it's important to compare this finding with existing knowledge and other studies' outcomes.

Consider a scenario where a vaccine trial fails to show efficacy in preventing a particular disease. If multiple other trials with different populations and methodologies also show the same result, then the external coherence of this negative outcome is high. This consensus would suggest that the vaccine might genuinely be ineffective.

On the other hand, if this trial is the only one showing a negative result while many others show positive outcomes, the external coherence is low. Factors like the study population's unique genetic makeup, differences in administering the vaccine, or even methodological flaws could be responsible.

By ensuring the external coherence of negative results, researchers can make informed decisions about whether to abandon a particular line of investigation or re-evaluate the study parameters to understand the discrepancy.


### 3.3 Explanation of Discordances

Discrepancies between studies are not uncommon, given the myriad factors that can influence outcomes in clinical trials. These factors range from the diversity in study populations, methodologies, geographical locations, and even the evolving nature of knowledge.

When faced with discordances in results, it's crucial to dive deep to unearth the underlying causes. Perhaps the participants in one trial had prior exposure to a similar intervention, thus influencing the outcome. Or maybe the discordance arises from differences in how outcomes were measured across trials.

For instance, two trials studying a new diabetes drug might use different metrics for success. While one could focus solely on blood sugar levels, the other might consider holistic factors like overall well-being, frequency of hypoglycemic episodes, and patient satisfaction. Such differences in outcome measures can lead to apparent discordances.

By understanding and explaining these discordances, researchers can offer a more comprehensive and nuanced perspective on a trial's findings. It ensures that the results are interpreted in context, making them more actionable and beneficial for future research and clinical applications.



## 4. Clinical Relevance of findings



### 4.1 Purpose of the Trial

Understanding the primary objective or purpose of a clinical trial is crucial for gauging its clinical relevance. Every clinical trial is designed to **answer specific questions**. This could range from assessing the **safety** profile of a new drug, understanding its **efficacy** compared to existing treatments, or evaluating its impact on patients' **quality of life**.

For example, while one trial might be designed to determine if a new drug can reduce the size of tumors in cancer patients, another might focus on whether the drug can improve patients' longevity. The purpose directs the

design, methodology, and outcome measures, and its clarity is paramount for translating results into meaningful clinical insights.

## 4.2 Appropriate Comparison Treatment

In clinical trials, especially those looking at therapeutic interventions, the choice of comparison treatment is pivotal. Usually, a new intervention is compared to a placebo or the current standard of care. The appropriateness of this comparator can significantly influence the trial's conclusions.

For instance, in a scenario where a new drug is compared to a placebo, it might show significant efficacy. However, if the same drug is compared to a well-established treatment, the results might be less impressive. Thus, understanding the rationale behind the chosen comparator and its relevance to real-world clinical scenarios is essential for interpreting the trial's significance.

## 4.3 Clinical Judgment Criterion

Clinical judgment goes beyond the black-and-white statistical outcomes of a trial. It encompasses a holistic understanding of the patient, considering both quantitative results and qualitative factors like the patient's values, preferences, and overall context.

In some instances, a treatment might show statistical significance but might not lead to a meaningful improvement in the patient's quality of life. For example, a drug might reduce the frequency of migraines but also come with side effects that some patients find intolerable. In such scenarios, clinical judgment helps healthcare professionals weigh the pros and cons and make decisions tailored to individual patients.

## 4.4 Concomitant Treatments

Many patients, especially those with chronic conditions, might be on multiple medications or treatments simultaneously. Understanding the interactions and combined effects of these concomitant treatments is crucial.

For instance, in a trial evaluating a new heart medication, some participants might also be taking cholesterol-lowering drugs. If not appropriately accounted for, these concomitant treatments can confound the results,

making it challenging to isolate the new drug's effects. Recognizing and controlling for such scenarios ensures the trial's results genuinely reflect the intervention's impact.

#### **4.5 Evaluated Treatment Practicability**

For a treatment to be clinically relevant, it should not only be effective but also practicable. This encompasses various factors like ease of administration, frequency of dosing, storage requirements, and cost.

Consider a potent new vaccine that requires storage at extremely low temperatures and multiple doses spread over many months. While it might be effective, its practicability could be limited, especially in resource-poor settings. Assessing and addressing such factors ensure that treatments can be widely adopted and benefit the maximum number of patients.

#### **4.6 Representation of Patients Included in the Trial**

A clinical trial's results are most relevant when its participants accurately reflect the broader population that the treatment aims to serve. Factors like age, gender, ethnicity, and underlying health conditions can influence treatment outcomes.

For instance, a drug trialed predominantly in young males might not have the same efficacy in older females. Ensuring diverse and representative participation in trials ensures their findings are generalizable and clinically relevant to the broader patient population.

#### **4.7 Accuracy and Precision of Results**

##### **4.7.1 Confidence Interval**

The confidence interval (CI) provides a range within which the true population parameter is likely to fall, given a certain level of confidence. In clinical trials, the CI offers a measure of the reliability of the results. A narrower CI indicates that the study provides a more precise estimate, while a wider CI suggests greater uncertainty.

For instance, if a trial shows that a drug reduces the risk of a particular disease by 20% with a 95% CI of 15% to 25%, it suggests that we can be 95%

confident that the true risk reduction lies between 15% and 25%. The presence of this interval provides more context than a single point estimate and helps in understanding the range of potential outcomes.

#### **4.7.2 Interpretation**

Interpreting the results of a clinical trial goes beyond just looking at the numbers. It involves understanding the **practical significance of the findings** and how they can be applied in real-world clinical scenarios.

For example, a drug might show a statistically significant improvement in blood pressure readings. Still, the clinical significance might be minor, leading to questions about its **real-world value**. Conversely, even if a result is not statistically significant, it might have profound clinical implications. The art of interpretation requires a **nuanced understanding of both the statistical and clinical contexts**.

### **4.8 Benefit-Risk Assessment**

#### **4.8.1 Adverse Effects of Greater Severity than the Disease**

Any new intervention, be it a drug or a medical procedure, comes with potential risks. One critical aspect of clinical relevance is understanding when the adverse effects of an intervention could be more severe than the disease it aims to treat.


For instance, a potent chemotherapy drug might show efficacy in shrinking tumors. However, if it also leads to life-threatening complications in a significant portion of patients, its **overall benefit** might be questionable. Balancing the potential benefits against such severe risks is essential for informed clinical decisions.

#### **4.8.2 Adverse Effects Similar in Nature to the Disease**

It's also essential to **understand when an intervention's side effects mirror the symptoms or complications of the disease itself**.

Imagine a drug aimed at treating depression but has a side effect of inducing severe mood swings in some patients. In such cases, the line between treatment and potential harm becomes blurred. Recognizing these parallels

ensures that interventions don't inadvertently exacerbate the very conditions they aim to ameliorate.



## 5. Special Case of Negative Trials



Negative trials, where the intervention does not show a statistically significant benefit, are as crucial as positive ones. They **prevent the adoption of ineffective treatments**, guiding researchers and clinicians towards more promising avenues.

### 5.1 Superiority Trials

#### 5.1.1 Lack of Statistical Power



Lack of statistical power means that the trial might not have had enough participants or was not conducted long enough to detect a difference between the intervention and the control, even if one exists. For example, a trial might conclude that a new painkiller is not superior to an existing one. Still, if only a few participants were involved, this conclusion might be premature.

### **5.1.2 Conservatively Designed Trials**

Some trials are designed conservatively to err on the side of caution. In such trials, even minor discrepancies in results might be interpreted as a lack of superiority. Understanding the trial design's nuances helps in gauging the real implications of a negative result.

### **5.1.3 True Lack of Treatment Efficacy**

In some cases, negative trials genuinely reflect that the intervention is not effective. These results are invaluable, preventing the unnecessary use of ineffective treatments and guiding research towards alternative strategies.

## **5.2 Negative Non-inferiority Trials**

In non-inferiority trials, the goal is to prove that a new treatment is no worse than an existing standard of care. A negative result in such a trial suggests that the new intervention might be inferior. These findings are critical, especially when the new treatment offers other advantages, like being less expensive or having a more convenient dosing regimen.

## **Conclusion**

The critical evaluation of clinical trials serves as the cornerstone of evidence-based medicine. As illustrated, each component of a clinical trial, from its design to the interpretation of results, holds unique challenges and considerations. The internal validity of a trial ensures that the observed effects are due to the intervention itself and not external factors. External validity, on the other hand, ensures the generalizability of the trial's results to the broader patient population. Clinical relevance and the careful interpretation of findings ensure that the outcomes are meaningful in real-world settings.

The comprehensive assessment laid out in the chapters serves as a reminder of the complexities involved in clinical research. For medical professionals, researchers, and stakeholders, understanding these intricacies is vital. It ensures that the findings from clinical trials are not only statistically significant but also hold real-world value, ultimately guiding clinical decisions and patient care.

Ensuring rigorous design, execution, and interpretation of clinical trials will remain essential as medicine continues to evolve, ensuring patient safety and advancing therapeutic options for myriad health challenges.

### Other References:

#### 1. General Critical Reading and Analysis of Clinical Trials:

- Article Title: L'interprétation des essais cliniques
- Authors: F. Aptel, M. Cucherat, E. Blumen-Ohana, P. Denis
- Published in: Journal Français d'Ophtalmologie, Volume 34, Issue 10, December 2011, Pages 755-761<sup>12</sup>.

#### 2. Basic Concepts in Clinical Trial Design:

- Article Title: How to read a published clinical trial: A practical guide for...
- Description: Covers randomized and non-randomized clinical trial designs<sup>3</sup>.

#### 3. Methodological and Statistical Concepts in Clinical Trials:

- Article Title: [Critical reading of clinical trials]
- Authors: Not specified
- Description: Reviews methodological and statistical concepts required for the design and interpretation of clinical trials, including biases and statistical tests used in clinical trials<sup>4</sup>.

#### 4. Statistical Concepts in Clinical Trials:

- Article Title: Fundamental Statistical Concepts in Clinical Trials and...
- Description: Explores basic statistical concepts of clinical trial design and diagnostic testing<sup>5</sup>.

#### 5. Methodological and Statistical Issues in Phase 3 Clinical Trials:

- Article Title: Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet
- Published in: Volume 119, Issue 25, 21 June 2012, Pages 5963-5971<sup>6</sup>.

#### 6. Methods and Applications of Statistics in Clinical Trials:

- Book Title: Methods and Applications of Statistics in Clinical Trials, Volume 1: Concepts, Principles, Trials, and Designs

- Description: An excellent reference for researchers, practitioners, and students in the fields of clinical trials, pharmaceuticals, biostatistics, medical research design, biology, biomedicine, epidemiology, and public health.<sup>7</sup>

#### 7. **Commonly Used Statistical Methods in Clinical Trials:**

- Article Title: An overview of commonly used statistical methods in clinical...
- Description: Provides a brief overview of statistical methods frequently used in clinical research studies.<sup>8</sup>

#### 8. **Assessing Statistical Analyses of Clinical Trials:**

- Article Title: Assessing statistical analyses of clinical trials: primer in...
- Description: Presents a published "validity" tool for assessment and gives flowcharts to show which statistical tests can be used.<sup>9</sup>

#### 9. **Experimental Design in Clinical Research:**

- Article Title: Critical evaluation of clinical research
- Description: Presents elements of experimental design including clinical trials, randomization, single-subject design, meta-analysis, and epidemiological studies.<sup>10</sup>

#### 10. **Understanding Diagnostic Testing in the Context of Clinical Trials:**

- Article Title: Fundamental Statistical Concepts in Clinical Trials and Diagnostic Testing
- Authors: Stephanie L Pugh, Pedro A Torres-Saavedra
- Description: Explores statistical concepts related to diagnostic testing within the context of clinical trial design and analysis, published in the Journal of Nuclear Medicine, June 2021.<sup>5</sup>

*Prompted and Curated by Emmanuel Lacharme*

*Written by GPT-4*

*Illustrated by DALL-E*

*Diagrams by "AI Diagrams" Plugin*